The results show that the TME-responsive nanocomposite hydrogel possesses enhanced anti-tumor efficacy in MYC-amplified OS, which supports further development of rational combination therapy for MYC-amplified tumor treatment. The gene discussed is MYC; the disease is neoplasm.